Prescription medicine
Ceftobiprole medocaril Brand names: Zevtera
Ceftobiprole medocaril (Zevtera) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the ceftobiprole medocaril FDA label on DailyMed (effective July 2, 2026, La Jolla Pharmaceutical Company); the NDA 218275 record on Drugs@FDA; every ceftobiprole medocaril label on DailyMed.
Highlights of the record
FDA label of July 2, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneu
Forms and strengths
- 667 mg
Injection (powder) for solution.
On the market
- Earliest approval on file
- April 3, 2024 Zevtera, Istx; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 53 through July 30, 2026
What is ceftobiprole medocaril used for?
From the label: indications and usageZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). […]
FDA pharmacologic class: Cephalosporin Antibacterial.
Source: FDA drug label (ZEVTERA), NDA218275 (Istx), as published by La Jolla Pharmaceutical Company, effective July 2, 2026 (SPL set 2bd685df-7dc6-78a6-e063-6294a90a580b), via openFDA; the full label on DailyMed
Is there a generic for ceftobiprole medocaril (Zevtera)?
No generic ceftobiprole medocaril is approved (Drugs@FDA, October 8, 2026).
- 2024 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for ceftobiprole medocaril?
The FDA Adverse Event Reporting System holds 53 reports that list ceftobiprole medocaril among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 27 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other cephalosporins
- the pharmacologic class, with prices and generics
- Ceftobiprole medocaril side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other